Promises and challenges of targeting Bcl-2 anti-apoptotic proteins for cancer therapy

被引：76

作者：

O'Neill, J ^{[1
]}

Manion, M ^{[1
]}

Schwartz, P ^{[1
]}

Hockenbery, DM ^{[1
]}

机构：

[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2004年 / 1705卷 / 01期

关键词：

apoptosis; BCL-2; BCL-X; BH3; domain; molecular target; mitochondria;

D O I：

10.1016/j.bbcan.2004.09.004

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Cancer cells with elevated levels of BCL-2 and related survival proteins are broadly resistant to cytotoxic agents. Antisense oligodeoxynucleotides, and more recently small molecule ligands for BCL-2 and BCL-X-L, are directly cytotoxic or synergistic with standard cytotoxic agents, and in some cases, may demonstrate selectivity for tumor cells. The usual issues for rational drug discovery are writ large upon BCL-2-targeted therapeutics. The molecular functions of BCL-2 are not well understood, such that validation of cytotoxic mechanisms related to BCL-2 as well as identification of surrogate markers for BCL-2 function are significant obstacles for drug development. Despite these problems, a substantial number of small molecules that bind to BCL-2 or BCL-XL are now available for pre-clinical testing; in turn, basic studies with these reagents should yield new insights about optimal strategies to disrupt BCL-2 survival functions. (C) 2004 Elsevier B.V. All rights reserved.

引用

页码：43 / 51

页数：9

共 62 条

[1]

Amundson SA, 2000, CANCER RES, V60, P6101

[2] Critical upstream signals of cytochrome c release induced by a novel Bcl-2 inhibitor [J].